Kangmei Pharmaceutical Co., Ltd. Stock price

Equities

600518

CNE0000017M1

Pharmaceuticals

End-of-day quote Shanghai S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
2.09 CNY 0.00% Intraday chart for Kangmei Pharmaceutical Co., Ltd. -2.79% +12.37%
Sales 2021 4.15B 575M Sales 2022 4.18B 578M Capitalization 30.5B 4.22B
Net income 2021 7.92B 1.1B Net income 2022 -2.69B -372M EV / Sales 2021 9.78 x
Net cash position 2021 2.21B 306M Net cash position 2022 1.24B 172M EV / Sales 2022 7 x
P/E ratio 2021
5.42 x
P/E ratio 2022
-11.6 x
Employees 6,371
Yield 2021 *
-
Yield 2022
-
Free-Float 66.8%
More Fundamentals * Assessed data
Dynamic Chart
Court Dismisses Winding-Up Petition Against Kangmei Pharma's Unit MT
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
China’s Securities Regulator Fines 37 Brokerages Since H1 2019 MT
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Former Kangmei Chairman Loses Appeal Against 12-Year Sentence MT
Kangmei Pharmaceutical Co., Ltd. announced that it has received CNY 6.5 billion in funding from Guangdong Shennong Enterprise Management Partnership (Limited Partnership), GF Securities Co., Ltd., Investment Arm, Wuhu Xintongrui Enterprise Management Center (Limited Partnership), Shenzhen Zhaoping Linghang Investment Center (Limited Partnership), China Resources Shenzhen International Investment Trust Co., Ltd. CI
Kangmei Pharmaceutical Co., Ltd. announced that it expects to receive CNY 6.5 billion in funding from Guangdong Shennong Enterprise Management Partnership (Limited Partnership), GF Securities Co., Ltd., Investment Arm, Wuhu Xintongrui Enterprise Management Center (Limited Partnership), Shenzhen Zhaoping Linghang Investment Center (Limited Partnership), China Resources Shenzhen International Investment Trust Co., Ltd. CI
Kangmei Fraud Case Decision Triggers Exodus of Independent Directors From Listed Firms MT
Kangmei to Get $1 Billion Government-Led Bailout MT
Kangmei Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
More news
1 day-2.34%
1 week-2.79%
Current month+11.17%
1 month+9.42%
3 months+12.97%
6 months+13.59%
Current year+12.37%
More quotes
1 week
2.09
Extreme 2.09
2.33
1 month
1.85
Extreme 1.85
2.33
Current year
1.68
Extreme 1.68
2.33
1 year
1.68
Extreme 1.68
2.50
3 years
1.68
Extreme 1.68
5.16
5 years
1.66
Extreme 1.66
12.45
10 years
1.66
Extreme 1.66
28.25
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 20-10-09
Director of Finance/CFO 50 20-10-09
Investor Relations Contact 35 18-12-31
Members of the board TitleAgeSince
Director/Board Member 63 20-10-29
Chairman 59 20-10-29
Director/Board Member 62 22-01-24
More insiders
Date Price Change Volume
24-03-27 2.09 0.00% 167 304 700
24-03-27 2.09 -2.34% 162,371,200
24-03-26 2.14 -3.60% 261,493,000
24-03-25 2.22 -0.45% 339,702,900
24-03-22 2.23 +5.19% 255,506,200

End-of-day quote Shanghai S.E., March 26, 2024

More quotes
Kangmei Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products intended primarily for treating hypertension and colds. The group offers Chinese medications (ginseng, salvia, codonopsis, etc.) and chemical medications (clarithromycin, doxazosin mesylate, paracetamol, etc.). All sales are earned in China.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Kangmei Pharmaceutical Co., Ltd. - Shanghai S.E.